A YORK firm of scientists has entered into a five year agreement for the manufacture and supply of its cholesterol and blood pressure reducing products in India.

York Science Park-based Optibiotix Health, a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, has signed the agreement with Akums Drugs and Pharmaceuticals Ltd.

Under the terms of the agreement, Akums will manufacture and supply products containing OptiBiotix’s LPLDL strain throughout India to maximise the financial return for both parties.

Stephen O’Hara, chief executive of OptiBiotix, commented: “We are excited to announce this agreement.

“We chose Akums as they are the largest contract manufacturing company in India for both food supplements and pharmaceuticals and have extensive experience in manufacturing products for some of the biggest food and pharmaceutical companies in the world.”